John S Yu
CIK 1550545 · CEO and Chairman · last filed 2025-11-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMUC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WOODLAND HILLS, CA 91367
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KAPA | CEO and Chairman | 792,382 | $0.56 | $442.5K | $5.8K | 3 | 2025-11-26 |
| ImmunoCellular Therapeutics, Ltd. (IMUC.WS) Delisted | Director | 120,508 | — | — | $0 | 1 | 2018-06-08 |
| ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | Secretary | 77 | — | — | -$871.2K | 10 | 2016-06-21 |
Recent Filings · Page 2 of 2
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-10-22 | ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | Mixed | — | -$711.5K | EDGAR |
| 2013-09-24 | ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-06-17 | ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-12-18 | ImmunoCellular Therapeutics, Ltd. (IMUC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.